Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland
Zurich, Switzerland
Prof. Dr. Oliver Distler is Professor of Rheumatology at the University of Zurich and Head of the Department of Rheumatology at University Hospital Zurich in Switzerland. He is aldo heading the Center of Expertimental Rheumatology of the University of Zurich.
Prof. Dr. Distler earned his medical degree from the University of Erlangen in Germany in 1997. Subsequently, he completed his internship in internal medicine at Bamberg Hospital and his residency and fellowship at the University Hospital of Regensburg, both in Germany. Prof. Dr. Distler then did a postdoctoral fellowship in the Center of Experimental Rheumatology at the University of Zurich and additional fellowships in the Departments of Rheumatology and Clinical Immunology at University Hospital Zurich.
Prof. Dr. Distler’s research focuses on molecular mechanisms of inflammatory rheumatic diseases, the validation of biomarkers, the identification and characterization of animal models, and the design of proof-of-concept and phase 2/3 trials. He has authored over 354 papers on these topics, and he is a member of the editorial boards of Lancet Rheumatology and Annals of the Rheumatic Diseases.
Professor Distler is on the Board of Directors for several scientific organizations and initiatives in systemic sclerosis. He is currently Executive Chair of the EULAR-associated FOREUM Foundation
Meet the Panel: Case-Based Interstitial Lung Disease
Sunday, November 12, 2023
9:00 AM – 9:45 AM PT
Disclosure(s): 4P Pharma: Consultant (Ongoing); AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Acceleron: Consultant (Ongoing); Alcimed: Consultant (Ongoing); Altavant: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AnaMar: Consultant (Ongoing); Arxx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Blade: Consultant (Ongoing); Boehringer-Ingelheim: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Corbus: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); Galapagos: Consultant (Ongoing); Galderma: Consultant (Ongoing); Glenmark: Consultant (Ongoing); Gossamer: Consultant (Ongoing); Kymera: Consultant (Ongoing); Lupin: Consultant (Ongoing); Medscape: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Miltenyi Biotec: Consultant (Ongoing); Mitsubishi Tanabe: Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Prometheus: Consultant (Ongoing); Redxpharma: Consultant (Ongoing); Roivant: Consultant (Ongoing); Topadur: Consultant (Ongoing)
Wednesday, November 15, 2023
11:15 AM – 11:25 AM PT
Disclosure(s): 4P Pharma: Consultant (Ongoing); AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Acceleron: Consultant (Ongoing); Alcimed: Consultant (Ongoing); Altavant: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AnaMar: Consultant (Ongoing); Arxx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Blade: Consultant (Ongoing); Boehringer-Ingelheim: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Corbus: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); Galapagos: Consultant (Ongoing); Galderma: Consultant (Ongoing); Glenmark: Consultant (Ongoing); Gossamer: Consultant (Ongoing); Kymera: Consultant (Ongoing); Lupin: Consultant (Ongoing); Medscape: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Miltenyi Biotec: Consultant (Ongoing); Mitsubishi Tanabe: Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Prometheus: Consultant (Ongoing); Redxpharma: Consultant (Ongoing); Roivant: Consultant (Ongoing); Topadur: Consultant (Ongoing)